Infinant Health's Significant FDA Designations
Infinant Health, a privately-held company dedicated to improving health outcomes for infants, recently announced the U.S. Food and Drug Administration (FDA) designations for its investigational drug candidate, INF108. This drug has been granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD), specifically targeting necrotizing enterocolitis (NEC) prevention in preterm infants.
Understanding Necrotizing Enterocolitis
Necrotizing enterocolitis is a severe condition that can affect preterm infants and is characterized by the death of intestinal tissue. This serious condition arises when the intestinal lining becomes inflamed, leading to potential deterioration of the gut. Though the exact origins of NEC remain unclear, factors such as reduced blood flow to the bowel and harmful bacterial growth are believed to contribute significantly. NEC unfortunately remains a leading cause of mortality among premature infants every year, significantly impacting countless families.
The Impact of FDA Designations
Mike Johnson, CEO of Infinant Health, expressed optimism, stating, "Securing this Orphan Drug Designation sends a positive message to the neonatology community." The Rare Pediatric Disease Designation offers an opportunity for the company to receive a priority review voucher once INF108 gains approval, thus enhancing the pace of clinical development for this potentially life-saving treatment. This advancement promises to bring hope to families navigating the challenging landscape of NEC prevention.
Infinant Health's Clinical Trials and Future Outlook
The FDA offers the Orphan Drug Designation to therapies aimed at treating rare diseases that affect fewer than 200,000 individuals in the U.S. This designation comes with numerous advantages, including tax credits and exclusive marketing rights upon successful approval. Additionally, the RPDD allows for a priority review voucher upon INF108's approval before the expiration of the Rare Pediatric Disease program, set to sunset if Congress does not renew it by the deadline.
The Role of INF108 in Infant Health
Infinant Health is preparing to launch a human clinical trial utilizing its patented investigational drug, INF108, which is derived from the strain Bifidobacterium longum subspecies infantis. This innovative approach focuses on enhancing the gut health of preterm infants, contributing to better health outcomes in this vulnerable population.
About Infinant Health
Previously known as Evolve Biosystems, Infinant Health is committed to shifting the paradigm of infant health. Their mission revolves around fostering healthy immune development through gut microbiome science. With a burgeoning product pipeline, the company aims to promote optimal infant health. Notable past and present investors include the Bill Gates Foundation, Johnson & Johnson, and Cargill, along with other prominent institutions.
Frequently Asked Questions
What designations did Infinant Health receive from the FDA?
Infinant Health received both Orphan Drug Designation and Rare Pediatric Disease Designation for its drug INF108.
What is necrotizing enterocolitis?
Necrotizing enterocolitis (NEC) is a serious condition primarily affecting preterm infants, characterized by inflammation and tissue death in the intestines.
How does INF108 work?
INF108 is an investigational drug derived from a specific strain of bacteria aimed at promoting gut health in preterm infants.
What are the benefits of the FDA designations?
These designations provide benefits such as tax credits, marketing exclusivity, and a priority review voucher that can expedite the drug approval process.
What is Infinant Health’s mission?
Infinant Health's mission is to improve the trajectory of human health by focusing on the development of healthy immune systems through innovative gut microbiome science.
